331 related articles for article (PubMed ID: 33298062)
41. Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial.
Vogelmeier CF; Gaga M; Aalamian-Mattheis M; Greulich T; Marin JM; Castellani W; Ninane V; Lane S; Nunez X; Patalano F; Clemens A; Kostikas K;
Respir Res; 2017 Jul; 18(1):140. PubMed ID: 28720132
[TBL] [Abstract][Full Text] [Related]
42. Functional respiratory imaging assessment of budesonide/glycopyrrolate/formoterol fumarate and glycopyrrolate/formoterol fumarate metered dose inhalers in patients with COPD: the value of inhaled corticosteroids.
van den Berge M; De Backer J; Van Holsbeke C; De Backer W; Trivedi R; Jenkins M; Dorinsky P; Aurivillius M
Respir Res; 2021 Jul; 22(1):191. PubMed ID: 34210340
[TBL] [Abstract][Full Text] [Related]
43. Rapid effects of extrafine beclomethasone dipropionate/formoterol fixed combination inhaler on airway inflammation and bronchoconstriction in asthma: a randomised controlled trial.
O'Connor BJ; Collarini S; Poli G; Brindicci C; Spinola M; Acerbi D; Barnes PJ; Leaker B
BMC Pulm Med; 2011 Dec; 11():60. PubMed ID: 22188731
[TBL] [Abstract][Full Text] [Related]
44. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β
Ferguson GT; Darken P; Ballal S; Siddiqui MK; Singh B; Attri S; Holmgren U; de Nigris E
Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859
[TBL] [Abstract][Full Text] [Related]
45. AMPLIFY: a randomized, Phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD.
Sethi S; Kerwin E; Watz H; Ferguson GT; Mroz RM; Segarra R; Molins E; Jarreta D; Garcia Gil E
Int J Chron Obstruct Pulmon Dis; 2019; 14():667-682. PubMed ID: 30962681
[TBL] [Abstract][Full Text] [Related]
46. The Impact of Fixed Triple Therapy with Beclometasone/Formoterol/Glycopyrronium on Health Status and Adherence in Chronic Obstructive Pulmonary Disease (COPD) in an Italian Context of Real Life: The TRITRIAL Study Protocol.
Richeldi L; Piraino A; Macagno F; Micarelli G; Ingrassia E
Int J Chron Obstruct Pulmon Dis; 2021; 16():159-166. PubMed ID: 33536751
[TBL] [Abstract][Full Text] [Related]
47. Lung Deposition of the Dry Powder Fixed Combination Beclometasone Dipropionate Plus Formoterol Fumarate Using NEXThaler
Virchow JC; Poli G; Herpich C; Kietzig C; Ehlich H; Braeutigam D; Sommerer K; Häussermann S; Mariotti F
J Aerosol Med Pulm Drug Deliv; 2018 Oct; 31(5):269-280. PubMed ID: 29989511
[TBL] [Abstract][Full Text] [Related]
48. Efficacy and safety of four doses of glycopyrrolate/formoterol fumarate delivered via a metered dose inhaler compared with the monocomponents in patients with moderate-to-severe COPD.
Reisner C; Pearle J; Kerwin EM; Rose ES; Darken P
Int J Chron Obstruct Pulmon Dis; 2018; 13():1965-1977. PubMed ID: 29950826
[TBL] [Abstract][Full Text] [Related]
49. Early bronchodilator action of glycopyrronium versus tiotropium in moderate-to-severe COPD patients: a cross-over blinded randomized study (Symptoms and Pulmonary function in the moRnING).
Marin JM; Beeh KM; Clemens A; Castellani W; Schaper L; Saralaya D; Gunstone A; Casamor R; Kostikas K; Aalamian-Mattheis M
Int J Chron Obstruct Pulmon Dis; 2016; 11():1425-34. PubMed ID: 27418815
[TBL] [Abstract][Full Text] [Related]
50. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
[TBL] [Abstract][Full Text] [Related]
51. Extrafine Beclometasone Dipropionate/Formoterol Fumarate vs Double Bronchodilation Therapy in Patients with COPD: A Historical Real-World Non-Inferiority Study.
Voorham J; Baldi S; Santoro L; Kerkhof M; Contoli M; Fabbri LM; Kerstjens HAM; Luis López-Campos J; Roche N; Singh D; Vogelmeier CF; Price DB
Int J Chron Obstruct Pulmon Dis; 2020; 15():2739-2750. PubMed ID: 33149571
[TBL] [Abstract][Full Text] [Related]
52. A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD.
Tashkin DP; Martinez FJ; Rodriguez-Roisin R; Fogarty C; Gotfried M; Denenberg M; Gottschlich G; Donohue JF; Orevillo C; Darken P; St Rose E; Strom S; Fischer T; Golden M; Reisner C
Respir Med; 2016 Nov; 120():16-24. PubMed ID: 27817811
[TBL] [Abstract][Full Text] [Related]
53. Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations.
Wedzicha JA; Singh D; Vestbo J; Paggiaro PL; Jones PW; Bonnet-Gonod F; Cohuet G; Corradi M; Vezzoli S; Petruzzelli S; Agusti A;
Respir Med; 2014 Aug; 108(8):1153-62. PubMed ID: 24953015
[TBL] [Abstract][Full Text] [Related]
54. Ceiling effect of beclomethasone/formoterol/glycopyrronium triple fixed-dose combination in COPD: A translational bench-to-bedside study.
Rogliani P; Ora J; Girolami A; Rossi I; de Guido I; Facciolo F; Cazzola M; Calzetta L
Pulm Pharmacol Ther; 2021 Aug; 69():102050. PubMed ID: 34129945
[TBL] [Abstract][Full Text] [Related]
55. TRICOP - A Real-world effectiveness study with a single-inhaler extrafine triple therapy over 52 weeks in Austrian patients with COPD.
Marth K; Renner A; Pohl W
Respir Med; 2021 Jun; 182():106398. PubMed ID: 33901786
[TBL] [Abstract][Full Text] [Related]
56. Efficacy of aclidinium/formoterol 400/12 µg, analyzed by airflow obstruction severity, age, sex, and exacerbation history: pooled analysis of ACLIFORM and AUGMENT.
D'Urzo AD; Singh D; Donohue JF; Kerwin EM; Ribera A; Molins E; Chuecos F; Jarreta D; Gil EG
Int J Chron Obstruct Pulmon Dis; 2019; 14():479-491. PubMed ID: 30880938
[TBL] [Abstract][Full Text] [Related]
57. Triple therapy with salmeterol/fluticasone propionate 50/250 plus tiotropium bromide improve lung function versus individual treatments in moderate-to-severe Japanese COPD patients: a randomized controlled trial - Evaluation of Airway sGaw after treatment with tripLE.
Saito T; Takeda A; Hashimoto K; Kobayashi A; Hayamizu T; Hagan GW
Int J Chron Obstruct Pulmon Dis; 2015; 10():2393-404. PubMed ID: 26604737
[TBL] [Abstract][Full Text] [Related]
58. Efficacy and safety of fluticasone propionate/formoterol fumarate in pediatric asthma patients: a randomized controlled trial.
Płoszczuk A; Bosheva M; Spooner K; McIver T; Dissanayake S
Ther Adv Respir Dis; 2018; 12():1753466618777924. PubMed ID: 29857783
[TBL] [Abstract][Full Text] [Related]
59. The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorized by symptom status: a pooled analysis.
Miravitlles M; Chapman KR; Chuecos F; Ribera A; Gil EG
Int J Chron Obstruct Pulmon Dis; 2016; 11():2041-53. PubMed ID: 27621610
[TBL] [Abstract][Full Text] [Related]
60. Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal.
Vanfleteren L; Fabbri LM; Papi A; Petruzzelli S; Celli B
Int J Chron Obstruct Pulmon Dis; 2018; 13():3971-3981. PubMed ID: 30587953
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
